Erkan Kurt

Dr. Erkan Kurt

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Pain Practice
Verified
Journal Article
Closed access
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
EKErkan Kurt
Erkan Kurt
LKLinda Kollenburg
Linda Kollenburg
JHJamal Hasoon
Jamal Hasoon
SWSayed E. Wahezi
Sayed E. Wahezi
NSNicholas R. Storlie
Nicholas R. Storlie

1 December 2017 in World Neurosurgery
Verified
Journal Article
Closed access
EKErkan Kurt
Erkan Kurt
DHDylan Henssen
Dylan Henssen
MSMonique Steegers
Monique Steegers
MSMichiel Staal
Michiel Staal
UBUlrich Beese
Ulrich Beese
MMMaarten Moens
Maarten Moens

10 February 2022 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Closed access
EKErkan Kurt
Erkan Kurt
RNRobin K. Noordhof
Robin K. Noordhof
RDRobert van Dongen
Robert van Dongen
KVKris Vissers
Kris Vissers
DHDylan Henssen
Dylan Henssen
YEYvonne Engels
Yvonne Engels

11 August 2015 in Frontiers in Integrative Neuroscience
Verified
Journal Article
Open access
PDF file
EKErsoy Kocabicak
Ersoy Kocabicak
OAOnur Alptekin
Onur Alptekin
LALinda Ackermans
Linda Ackermans
PKPieter Kubben
Pieter Kubben
MKMark Kuijf
Mark Kuijf
Yasin TemelYasin Temel
Yasin Temel
Is there still need for microelectrode recording now the subthalamic nucleus can be well visualized with high field and ultrahigh MR imaging?

22 March 2024 in Pain Reports
Verified
Journal Article
Open access
LKLinda Kollenburg
Linda Kollenburg
EKErkan Kurt
Erkan Kurt
HAHisse Arnts
Hisse Arnts
SVSaman Vinke
Saman Vinke
Introduction: Central poststroke pain (CPSP) places a huge burden on patient lives because patients are often refractory to conventional strategies and have little chance for spontaneous recovery. A subset of patients is even given approval for euthanasia and is without any perspective. Because the anterior cingulate cortex historically seems to be a promising target for patients with both mental and chronic pain disorders, lesioning of this central “hub” with cingulotomy may be a useful strategy for medically refractory CPSP. However, limited research is available on cingulotomy for central pain. Hence, we represent a rare case in which cingulotomy is performed on a patient with CPSP. Objectives: To describe the potential of cingulotomy in a case with CPSP. Methods: The case presented in this study concerns a 60-year-old woman who experienced CPSP, caused by a hemorrhagic stroke in the basal ganglia and thalamus. The patient visited several centers and tried multiple off-label treatments; however, she was told nothing else could be done and was even given approval for euthanasia. Hence, anterior cingulotomy was performed. Results: After surgery, no transient adverse events occurred, except for vocabulary disturbances post stroke, which disappeared after several weeks. After 14 weeks, changes in pain behavior were observed, followed by a decreased pain intensity. At a later follow-up, the pain had completely disappeared. Conclusion: Anterior cingulotomy seems to be a suitable “last-resort” option for patients with CPSP. Future research, including homogenous groups, to define the best location for lesioning is required to allow the revival of this “old” technique in the current era.

15 March 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
LBL. Bleeker
L. Bleeker
MKMathilde Cornelia Maria Kouwenhoven
Mathilde Cornelia Maria Kouwenhoven
IHI. de Heer
I. de Heer
BLBirgit Lissenberg-Witte
Birgit Lissenberg-Witte
AGA. H. Gijsbers
A. H. Gijsbers
JBJacoline Bromberg
Jacoline Bromberg
Purpose: Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Methods: Adult medulloblastoma patients diagnosed between 2010 and 2018 were identified in the Dutch rare tumors registry or nationwide pathology database. Patients with intention to treat according to the national treatment protocol were included. Risk stratification was performed based on residual disease, histological subtype and extent of disease. All patients received postoperative radiotherapy [craniospinal axis 36 Gy/fossa posterior boost 19.8 Gy (14.4 Gy in case of metastases)]. High-risk patients received additional neoadjuvant (carboplatin-etoposide), concomitant (vincristine) and adjuvant chemotherapy (carboplatin-vincristine-cyclophosphamide) as far as feasible by toxicity. Methylation profiling, and additional next-generation sequencing in case of SHH-activated medulloblastomas, were performed. Results: Forty-seven medulloblastoma patients were identified, of whom 32 were treated according to the protocol. Clinical information and tumor material was available for 28 and 20 patients, respectively. The histological variants were mainly classic (43%) and desmoplastic medulloblastoma (36%). Sixteen patients (57%) were considered standard-risk and 60% were SHH-activated medulloblastomas. Considerable treatment reductions and delays in treatment occurred due to especially hematological and neurotoxicity. Only one high-risk patient could complete all chemotherapy courses. 5-years progression-free survival (PFS) and overall survival (OS) for standard-risk patients appeared worse than for high-risk patients (PFS 69% vs. 90%, OS 81% vs. 90% respectively), although this wasn’t statistically significant. Conclusion: Combined chemo-radiotherapy is a toxic regimen for adult medulloblastoma patients that may result in improved survival.